What is the relation between the usage of GLP-1 analogs and obesity treatment?

Authors

DOI:

https://doi.org/10.33448/rsd-v12i10.43327

Keywords:

Obesity; Glucagon-like peptide 1; Drug therapy.

Abstract

Obesity is a global public health problem, which finds itself in a growing number of cases. This illness is associated with high morbimortality in the population and also various pathologies, such as diabetes mellitus type 2 and cardiovascular diseases. The main therapeutic intervention for this condition is lifestyle changes, contemplated by the practice of physical exercises, linked to hypocaloric diets. Nevertheless, plenty of patients don't obtain success in treating this infirmity, due to diligence and psychosocial factors intrinsic to this infirmity. In this scenario, GLP-1 analogs emerge as effective medicines in obesity treatment in patients who have no improvement with lifestyle changes isolated. In light of this, the article at stake aims to discuss the relationship between the usage of GLP-1 analogs and obesity treatment, highlighting its effects on weight loss and its limitations. It's, therefore, a literature integrative review, which was guided by parameters such as elaboration of a guiding question and keywords, inclusion and exclusion criteria, data gathering, and critical analysis of included surveys. To this end, surveys from the last 5 years that answered the leading and fit the inclusion and exclusion criteria question were utilized. The following survey, thus, emphasizes that GLP-1 analogs have effects on weight loss, glycemia, and cardiovascular risk.

References

Ard, J., Fitch, A., Fruh, S., & Herman, L. (2021). Perda e manutenção de peso relacionada ao mecanismo de ação dos agonistas do receptor do peptídeo 1 semelhante ao glucagon. Avanços na terapia, 38 (6), 2821-2839.

Barritt 4th, A. S., Marshman, E., & Noureddin, M. (2022). Papel dos agonistas do receptor do peptídeo 1 semelhante ao glucagon na esteato-hepatite não alcoólica, obesidade e diabetes - o que os hepatologistas precisam saber. Alimentary Pharmacology & Therapeutics, 55 (8), 944-959.

Burcelin, R., & Gourdy, P. (2017). Harnessing glucagon‐like peptide‐1 receptor agonists for the pharmacological treatment of overweight and obesity. Obesity Reviews, 18(1), 86-98.

D'Marco, L., et al. (2021). SGLT2i e GLP-1RA em doenças cardiometabólicas e renais: do controle glicêmico à inflamação e senescência do tecido adiposo. Journal of Diabetes Research, 2021(1), 1-17.

de Lima Dantas, H. L., Costa, C. R. B., Costa, L. D. M. C., Lúcio, I. M. L., & Comassetto, I. (2022). Como elaborar uma revisão integrativa: sistematização do método científico. Revista Recien-Revista Científica de Enfermagem, 12(37), 334-345.

Moraes, A. L. S. M. de., et al. (2022). Adverse effects of semaglutide compared to liraglutide: an integrative literature review. Research, Society and Development, 11(10), 579111033181. https://doi.org/10.33448/rsd-v11i10.33181

Kim, H. S. & Jung, C. H. (2021). Oral Semaglutide, the first ingestible glucagon-like peptide-1 receptor agonist: Could it be a magic bullet for type 2 diabetes?. International. Journal of Molecular Sciences, 22(18), 9936.

Mejía-Zambrano, H. (2022). Efectos de los agonistas del receptor de péptido similar al glucagón tipo 1 como tratamiento en pacientes con obesidad y diabetes mellitus tipo 2. Revista Habanera de Ciencias Médicas, 21(3), 4408.

Nigro, A. H. L., et al. (2021). Medicamentos utilizados no tratamento da obesidade: revisão de literatura. International Journal of Health Management Review, 7 (3), 0277. https://doi.org/10.37497/ijhmreview.v7i3.277

Overgaard, R. V., et al. (2021). Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes. Cell Reports Medicine, 2(9), 100387.

Pan, C. S. & Stanley, T. L. (2020). Efeito de medicamentos para perda de peso na esteatose hepática e esteato-hepatite: uma revisão sistemática. Frontiers in Endocrinology, 11(1), 70.

Pickford, P., et al. (2021). Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist. Molecular metabolism, 51(1), 101242.

Rubino, D. M., et al. (2022). Efeito da semaglutida subcutânea semanal versus liraglutida diária no peso corporal em adultos com sobrepeso ou obesidade sem diabetes: o estudo clínico randomizado STEP 8. JAMA, 327 (2), 138-150.

Souza, M. T. D., et al. (2010). Revisão integrativa: o que é e como fazer. Einstein, 8(1), 102-106.

Tilinca, M. C., et al. (2021). Uma atualização de 2021 sobre o uso de liraglutida no tratamento moderno de 'Diabesidade': uma revisão narrativa. Medicina, 57 (7), 669.

Trenson, L., et al. (2022). Liraglutida para controle de peso no mundo real: perda significativa de peso, mesmo que a dose diária máxima não seja atingida. Obesity Facts, 15 (1), 83-89.

Volpe, S., et al. (2022). A semaglutida uma vez por semana induz uma melhora precoce na composição corporal em pacientes com diabetes tipo 2: um estudo prospectivo da vida real de 26 semanas. Nutrientes, 14 (12), 2414.

Wharton, S., et al. (2019). Eficácia clínica do mundo real de liraglutida 3,0 mg para controle de peso no Canadá. Obesity, 27 (6), 917-924.

Wilding, J. P., et al. (2021). Semaglutida uma vez por semana em adultos com sobrepeso ou obesidade. New England Journal of Medicine, 384 (11), 989-1002.

Williams, D. M., Staff, M., Bain, S. C., & Min, T. (2022). Glucagon-like peptide-1 receptor analogues for the treatment of obesity. Touch reviews in Endocrinology, 18(1), 43.

Downloads

Published

03/10/2023

How to Cite

MALTA, L. M. .; CACAU , B. L. .; SANTOS, L. R. .; LYRA-PEREIRA, J.; REMÉDIOS , G. S. dos .; SOUSA, M. V. S. e .; ARAÚJO, A. L. S. de C. .; ROCHA, J. S. .; LIMA, B. W. P. R. .; MENDES, Érica de A. S. . What is the relation between the usage of GLP-1 analogs and obesity treatment?. Research, Society and Development, [S. l.], v. 12, n. 10, p. e26121043327, 2023. DOI: 10.33448/rsd-v12i10.43327. Disponível em: https://www.rsdjournal.org/index.php/rsd/article/view/43327. Acesso em: 14 may. 2024.

Issue

Vol. 12 No. 10

Section

Health Sciences

License

Copyright (c) 2023 Luana Mazza Malta; Bianca Lopes Cacau ; Livia Rocha Santos; Juliana Lyra-Pereira; Graziela Santos dos Remédios ; Marcus Vinicius Santos e Sousa; Andressa Lianna Soares de Carvalho Araújo; Jamilly Santiago Rocha; Bruno Walison Pontes Ribeiro Lima; Érica de Araújo Silva Mendes

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.